Bassett Hargrove Investment Counsel’s Pfizer PFE Stock Holding History

Bassett Hargrove Investment Counsel’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,012	Closed	-$411K	–	48
2023 Q2	$411K	Hold	8,012	–	–	0.77%	40
2023 Q1	$327K	Hold	8,012	–	–	0.57%	43
2022 Q4	$411K	Sell	8,012 -579	-7%	-$27.8K	0.77%	40
2022 Q3	$376K	Buy	+8,591	New	+$417K	0.76%	38
2022 Q1	$515K	Sell	9,940 -248	-2%	-$12.9K	0.79%	37
2021 Q4	$602K	Buy	10,188 +1,702	+20%	+$84.3K	0.87%	35
2021 Q3	$332K	Hold	8,486	–	–	0.49%	43
2021 Q2	$332K	Buy	+8,486	New	+$330K	0.49%	43

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bassett Hargrove Investment Counsel's PFE Position: Q3 2023 in Review

Bassett Hargrove Investment Counsel sold out of Pfizer (PFE) in Q3 2023, closing a stake of 8,012 shares — an estimated $411K sold.

Bassett Hargrove Investment Counsel first reported a position in PFE in Q2 2021 and held it in 8 quarters. The position peaked at $602K in Q4 2021. 2,928 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

Bassett Hargrove Investment Counsel reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
Bassett Hargrove Investment Counsel sold 8,012 Pfizer shares in Q3 2023, an estimated $411K.
Bassett Hargrove Investment Counsel first reported a position in Pfizer in Q2 2021 and held it in 8 quarters.
Bassett Hargrove Investment Counsel's Pfizer position peaked at $602K in Q4 2021.
2,928 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Bassett Hargrove Investment Counsel's 13F filing for Q3 2023, filed 26 Oct 2023.